Navigation Links
Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
Date:10/25/2007

Study Shows ADHD Patch Provides Tolerable and Effective Symptom Control

BOSTON, Oct. 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANA(TM) (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years. The study data was presented today at a major scientific and educational meeting of child and adolescent psychiatrists held in Boston, and is consistent with data previously presented.

"In our study, children with ADHD experienced effective ADHD symptom control improvement when using DAYTRANA for 12 months, improving their ability to maintain focus and concentration in and outside of the classroom," reported investigator Frank A. Lopez, M.D., neurodevelopmental pediatrician at the Children's Developmental Center, Winter Park, Fla. "Importantly, this year- long study showed that DAYTRANA maintained a favorable safety profile throughout the study period, with adverse events consistent with previous DAYTRANA studies."

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. The study results demonstrate that adverse events associated with DAYTRANA were similar to other methylphenidate products. The most common adverse events reported in this study were decreased appetite, headache, upper respiratory tract infection, cough, fever, and decreased weight. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
3. 8-Year Long-term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission with Bexxar
4. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
5. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
6. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
7. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
8. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. UCB Presents Long-Term CImzia Data in Crohns Disease
11. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... -- Inmark,s acquisition of Saf-T-Pak last week positioned Inmark ... Division 6.2.  For over 25 years, Saf-T-Pak has ... on IATA, ICAO, US DOT, Transport Canada, RID/ADR ... were particularly interested in Saf-T-Pak,s proprietary Learning Management ... programs," said David Oyler , Inmark President ...
(Date:4/21/2015)... April 21, 2015 Global cap ... World demand for caps and closures will exceed $55 billion ... exceed two trillion annually. Beverages will continue to account for ... and a number of smaller markets are expected to register ... Although the most developed markets -- the US, ...
(Date:4/21/2015)... 2015 The global dermatology diagnostic devices market ... from 2014 to 2019. North America ... shares in the global dermatology diagnostic devices market. The ... mainly attributed to a wide range of factors, such ... dermatologists, and technological advancements made in the field of ...
Breaking Medicine Technology:Inmark's Acquisition Of Saf-T-Pak Results In Expansion Of Its Dangerous Goods Training Portfolio 2World Caps & Closures Market 2World Caps & Closures Market 3Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 2Dermatology Diagnostic Devices Market by Product, by End-User - Global Forecast to 2019 3
... and NEW YORK, July 14, 2011 ... company leveraging its proprietary drug-delivery platforms to develop treatments ... announced that its lead product for oral mucositis, ... benefit network.  Reimbursement coverage for MuGard is now available ...
... BLUE BELL, Pa., July 14, 2011 Inovio Pharmaceuticals, ... in the development of therapeutic and preventive vaccines against ... cell and antibody responses were generated in its Phase ... for the prevention of avian H5N1 influenza delivered using ...
Cached Medicine Technology:Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 2Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 3Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 2Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 3Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 4Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 5Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 6Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 7Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 8Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I 9
(Date:4/21/2015)... “ ZeroWire ” was featured on NewsWatch as ... look at the latest and coolest technology products and ... for NewsWatch and a technology expert, conducted the review ... system and lifestyle management hub. , According to the ... burglaries in 2010. It goes without saying that home ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 21, 2015 ... Review, H1 2015” provides comparative analysis on ... strengthens R&D pipelines by identifying new targets ... products. Complete report with TOC is available ... report also reviews key players involved in ...
(Date:4/21/2015)... NJ (PRWEB) April 21, 2015 ... across platforms and devices, today announced a new enhancement ... of the new Microsoft Office 365 Management Activity API. ... customers to fully audit and take action on all ... , “The new Office 365 Management Activity API provides ...
(Date:4/21/2015)... York, NY (PRWEB) April 21, 2015 ... of advanced delivery technologies and development solutions for ... the launch of ADVASEPT™ Lock, a stopper-less, glass- ... delivery of injectable medications. Easily opened, ADVASEPT Lock ... convenient and functional container closure with the security ...
(Date:4/21/2015)... 2015 The report “Dermatitis ... analysis on the therapeutic development for Dermatitis. ... identifying new targets and MOAs to produce ... TOC is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html ... players involved in the therapeutic development for ...
Breaking Medicine News(10 mins):Health News:A Leader in Home Security was Featured on NewsWatch Television 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4
... Smoking has been linked to a number of ... disorders, among others. Early smoking is shown to ... disorders (e.g., panic disorder, generalized anxiety disorder), and ... anxiety) increases the risk for later development of ...
... now become common place owing to the wide scale ... over again, scientists have been working on ways to ... results of a recent research have recently confirmed that ... diseases. ,The leeches have added to the ...
... A new study says that botulinum toxin can be useful ... trigeminal neuralgia. Botulinum or botox as it is popularly known ... and eye spasms. ,Researchers in Brazil and the United ... have detailed their findings in a study published in the ...
... Kollywood stars like Kamal Hassan, Chiranjeevi, Nagarjuna, Venkatesh, Vikram, ... to spread the awareness on AIDS. ,The show ... the Melinda and Bill Gates Foundation was an evening of ... anything in partnership with others. I am very proud of ...
... is likely to invoke the compulsory licensing (CL) provision ... //firms to produce and stockpile Swiss drug maker Roche’s ... against the most dreaded avian flu virus. , ... receipt of an application from the industry. Furthermore, the ...
... Abdominal wall hernias are one of the most common ... repairs// performed annually. Although ventral hernia repair (VHR) is ... problem. Wound infection has been identified as a consistent ... recent study, which appears in the November issue of ...
Cached Medicine News:Health News:Smokers Are Prone To Number Of Psychiatric Disorders 2Health News:Leeches Provide Clues Regarding The Prevention Of Heart Disease 2Health News:Predictors Of Wound Infection In Ventral Hernia Repair 2
Inquire...
The autoclavable, aluminum needle box is designed to store loaded needles and help protect personnel from exposure. Each shield consists of an aluminum box with faceplate to match the grid pattern th...
... Brachytherapy loaders allow for efficient, easy ... Connectors to your customized plans at ... Bard loaders is the flexibility to ... in the QuickLoad™ Loader allows for ...
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
Medicine Products: